ZSP-1602

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameZSP-1602
Drug Alias NameZSP-1602
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsSmall Cell Lung CarcinomaPancreatic NeoplasmsStomach Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Zhongsheng Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangdong Zhongsheng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaPancreatic NeoplasmsCarcinoma, Basal Cell +[7] 
Inactive IndicationsStomach NeoplasmsEsophageal NeoplasmsCarcinoma, Neuroendocrine +[5] 

Other Information

ATC CodeN/A
Related LinksN/A